| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cloud Computing | 5 | 2024 | 13 | 2.760 |
Why?
|
| Genomics | 13 | 2024 | 777 | 2.330 |
Why?
|
| Software | 10 | 2023 | 666 | 2.170 |
Why?
|
| Neoplasms | 18 | 2024 | 3082 | 1.780 |
Why?
|
| Information Dissemination | 7 | 2024 | 116 | 1.740 |
Why?
|
| Biomedical Research | 8 | 2024 | 400 | 1.660 |
Why?
|
| Genome, Human | 8 | 2021 | 792 | 1.560 |
Why?
|
| Electronic Health Records | 3 | 2024 | 351 | 1.440 |
Why?
|
| Databases, Factual | 7 | 2024 | 860 | 1.100 |
Why?
|
| Datasets as Topic | 3 | 2017 | 75 | 1.030 |
Why?
|
| Veterans | 2 | 2024 | 85 | 1.010 |
Why?
|
| Databases, Genetic | 3 | 2021 | 269 | 0.970 |
Why?
|
| Vocabulary, Controlled | 1 | 2023 | 13 | 0.870 |
Why?
|
| National Cancer Institute (U.S.) | 6 | 2024 | 73 | 0.860 |
Why?
|
| Genome, Bacterial | 3 | 2022 | 149 | 0.860 |
Why?
|
| Computational Biology | 6 | 2019 | 550 | 0.850 |
Why?
|
| Data Accuracy | 2 | 2022 | 32 | 0.830 |
Why?
|
| Medical Informatics | 2 | 2024 | 49 | 0.830 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2022 | 12 | 0.800 |
Why?
|
| Whole Genome Sequencing | 2 | 2022 | 100 | 0.800 |
Why?
|
| Antitubercular Agents | 1 | 2022 | 54 | 0.790 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 52 | 0.770 |
Why?
|
| Medical Oncology | 4 | 2024 | 385 | 0.760 |
Why?
|
| Precision Medicine | 9 | 2024 | 414 | 0.750 |
Why?
|
| Drosophila melanogaster | 6 | 2014 | 614 | 0.710 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2022 | 195 | 0.670 |
Why?
|
| Disease | 2 | 2017 | 90 | 0.660 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 530 | 0.660 |
Why?
|
| Gene Regulatory Networks | 3 | 2010 | 310 | 0.630 |
Why?
|
| Mutation | 6 | 2024 | 4167 | 0.610 |
Why?
|
| Spatial Analysis | 1 | 2017 | 7 | 0.590 |
Why?
|
| Information Storage and Retrieval | 4 | 2023 | 121 | 0.590 |
Why?
|
| Data Collection | 1 | 2018 | 376 | 0.560 |
Why?
|
| Neuroblastoma | 2 | 2019 | 400 | 0.550 |
Why?
|
| Humans | 53 | 2024 | 89760 | 0.540 |
Why?
|
| Algorithms | 5 | 2018 | 1892 | 0.540 |
Why?
|
| Genome-Wide Association Study | 4 | 2020 | 1682 | 0.530 |
Why?
|
| United States | 15 | 2024 | 7037 | 0.480 |
Why?
|
| Liquid Biopsy | 4 | 2024 | 36 | 0.470 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 714 | 0.460 |
Why?
|
| Computer Systems | 1 | 2014 | 79 | 0.450 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 849 | 0.450 |
Why?
|
| Data Mining | 2 | 2014 | 43 | 0.410 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1981 | 0.410 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 1793 | 0.410 |
Why?
|
| DNA Methylation | 4 | 2021 | 659 | 0.400 |
Why?
|
| Systems Biology | 1 | 2012 | 44 | 0.390 |
Why?
|
| Databases, Nucleic Acid | 1 | 2011 | 41 | 0.370 |
Why?
|
| Molecular Sequence Annotation | 3 | 2021 | 71 | 0.370 |
Why?
|
| Phenotype | 5 | 2022 | 2450 | 0.360 |
Why?
|
| Transcription Factors | 7 | 2014 | 1657 | 0.360 |
Why?
|
| Models, Statistical | 2 | 2018 | 576 | 0.330 |
Why?
|
| User-Computer Interface | 3 | 2021 | 187 | 0.330 |
Why?
|
| Models, Molecular | 2 | 2004 | 1308 | 0.320 |
Why?
|
| Base Sequence | 5 | 2021 | 2331 | 0.310 |
Why?
|
| Reproducibility of Results | 6 | 2023 | 2766 | 0.300 |
Why?
|
| Genome, Insect | 3 | 2014 | 77 | 0.290 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1558 | 0.280 |
Why?
|
| Computer Security | 3 | 2019 | 16 | 0.280 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 868 | 0.280 |
Why?
|
| Computer Graphics | 1 | 2006 | 100 | 0.270 |
Why?
|
| Multiple Sclerosis | 4 | 2002 | 274 | 0.270 |
Why?
|
| Genome | 1 | 2009 | 390 | 0.270 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 300 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 2355 | 0.240 |
Why?
|
| Computer Communication Networks | 2 | 2016 | 23 | 0.240 |
Why?
|
| Chemistry | 1 | 2004 | 54 | 0.230 |
Why?
|
| Organic Chemicals | 1 | 2004 | 34 | 0.230 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 988 | 0.230 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2014 | 154 | 0.220 |
Why?
|
| Halomonadaceae | 2 | 2013 | 4 | 0.220 |
Why?
|
| Chromatin | 5 | 2014 | 400 | 0.210 |
Why?
|
| Internet | 3 | 2017 | 321 | 0.210 |
Why?
|
| Terminology as Topic | 1 | 2004 | 221 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 48 | 0.200 |
Why?
|
| Models, Biological | 1 | 2009 | 1767 | 0.200 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 125 | 0.200 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2011 | 137 | 0.200 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 150 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2003 | 92 | 0.190 |
Why?
|
| 5-Methylcytosine | 2 | 2019 | 117 | 0.180 |
Why?
|
| Specimen Handling | 1 | 2021 | 102 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2002 | 3473 | 0.180 |
Why?
|
| Viruses | 1 | 2021 | 78 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2022 | 191 | 0.170 |
Why?
|
| Chromothripsis | 1 | 2020 | 8 | 0.170 |
Why?
|
| Academic Success | 1 | 2020 | 11 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 961 | 0.170 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 182 | 0.170 |
Why?
|
| Veterans Health | 1 | 2019 | 16 | 0.170 |
Why?
|
| Oncogenes | 1 | 2020 | 98 | 0.170 |
Why?
|
| Telomerase | 1 | 2020 | 67 | 0.170 |
Why?
|
| Mutagenesis | 1 | 2020 | 203 | 0.170 |
Why?
|
| Cellular Senescence | 1 | 2020 | 104 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 343 | 0.160 |
Why?
|
| Telomere | 1 | 2020 | 120 | 0.160 |
Why?
|
| Ecosystem | 2 | 2023 | 349 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 2370 | 0.160 |
Why?
|
| Epigenomics | 1 | 2019 | 103 | 0.160 |
Why?
|
| Prognosis | 3 | 2022 | 3802 | 0.160 |
Why?
|
| Schools, Medical | 1 | 2020 | 134 | 0.160 |
Why?
|
| Access to Information | 1 | 2018 | 28 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 83 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 81 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 419 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1050 | 0.150 |
Why?
|
| RNA Splicing | 1 | 2020 | 156 | 0.150 |
Why?
|
| Mexican Americans | 1 | 2017 | 67 | 0.150 |
Why?
|
| Male | 8 | 2024 | 42632 | 0.150 |
Why?
|
| Quantitative Trait Loci | 2 | 2018 | 611 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2022 | 2882 | 0.140 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 349 | 0.140 |
Why?
|
| Models, Genetic | 2 | 2013 | 948 | 0.140 |
Why?
|
| Research | 1 | 2018 | 252 | 0.140 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 98 | 0.140 |
Why?
|
| Brain | 4 | 2002 | 2289 | 0.140 |
Why?
|
| Computing Methodologies | 1 | 2016 | 9 | 0.140 |
Why?
|
| Hemiptera | 2 | 2013 | 7 | 0.130 |
Why?
|
| Pandemics | 1 | 2022 | 776 | 0.130 |
Why?
|
| Phylogeny | 1 | 2022 | 1190 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 487 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2021 | 556 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 269 | 0.130 |
Why?
|
| DNA, Bacterial | 2 | 2013 | 244 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1253 | 0.120 |
Why?
|
| Symbiosis | 2 | 2013 | 127 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 1124 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 154 | 0.120 |
Why?
|
| Students, Medical | 1 | 2020 | 421 | 0.120 |
Why?
|
| Genetic Variation | 2 | 2018 | 1380 | 0.120 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2011 | 78 | 0.110 |
Why?
|
| Gene Expression | 1 | 2018 | 1310 | 0.110 |
Why?
|
| Erythroid Cells | 1 | 2013 | 14 | 0.110 |
Why?
|
| Systems Integration | 1 | 2014 | 36 | 0.110 |
Why?
|
| Erythropoiesis | 1 | 2013 | 51 | 0.110 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1666 | 0.110 |
Why?
|
| Binding Sites | 3 | 2014 | 1120 | 0.110 |
Why?
|
| Female | 9 | 2020 | 46439 | 0.110 |
Why?
|
| Metagenomics | 1 | 2014 | 91 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1599 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2024 | 9100 | 0.110 |
Why?
|
| Public-Private Sector Partnerships | 2 | 2024 | 6 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2012 | 79 | 0.100 |
Why?
|
| Models, Chemical | 2 | 2004 | 179 | 0.100 |
Why?
|
| Biotechnology | 1 | 2012 | 28 | 0.100 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 1160 | 0.100 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 231 | 0.100 |
Why?
|
| Child | 5 | 2019 | 7209 | 0.100 |
Why?
|
| Animals | 10 | 2024 | 27456 | 0.100 |
Why?
|
| Gene Components | 1 | 2011 | 6 | 0.100 |
Why?
|
| Leukemia, Myeloid | 1 | 2012 | 249 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1281 | 0.090 |
Why?
|
| Quality Control | 1 | 2011 | 117 | 0.090 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1451 | 0.090 |
Why?
|
| Forecasting | 1 | 2012 | 306 | 0.090 |
Why?
|
| Conserved Sequence | 1 | 2011 | 211 | 0.090 |
Why?
|
| Research Design | 1 | 2014 | 601 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2017 | 2020 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2012 | 424 | 0.080 |
Why?
|
| Machine Learning | 2 | 2024 | 263 | 0.080 |
Why?
|
| Radiology | 1 | 2012 | 201 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1180 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 559 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2018 | 1102 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 277 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 730 | 0.080 |
Why?
|
| Drosophila Proteins | 2 | 2010 | 510 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 479 | 0.070 |
Why?
|
| Aged | 3 | 2022 | 19280 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 3019 | 0.070 |
Why?
|
| Spinal Cord | 2 | 1998 | 255 | 0.070 |
Why?
|
| Spinal Canal | 1 | 1986 | 4 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2416 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2018 | 8283 | 0.060 |
Why?
|
| Facial Injuries | 1 | 1985 | 20 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 219 | 0.060 |
Why?
|
| Craniocerebral Trauma | 1 | 1985 | 56 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 1242 | 0.060 |
Why?
|
| Genotype | 2 | 2018 | 1852 | 0.050 |
Why?
|
| Xenobiotics | 1 | 2003 | 7 | 0.050 |
Why?
|
| Database Management Systems | 1 | 2003 | 41 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2019 | 2488 | 0.050 |
Why?
|
| Proteomics | 1 | 2024 | 230 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2014 | 284 | 0.040 |
Why?
|
| College Admission Test | 1 | 2020 | 2 | 0.040 |
Why?
|
| Histones | 2 | 2013 | 331 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 61 | 0.040 |
Why?
|
| School Admission Criteria | 1 | 2020 | 23 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 31 | 0.040 |
Why?
|
| Protein Binding | 2 | 2014 | 1490 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2019 | 150 | 0.040 |
Why?
|
| Infant | 3 | 2019 | 3171 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 436 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2019 | 3752 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 3027 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 642 | 0.040 |
Why?
|
| Family Health | 1 | 2017 | 162 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 114 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 95 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 873 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1270 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2016 | 6 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 213 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2016 | 40 | 0.030 |
Why?
|
| Government Regulation | 1 | 2016 | 49 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 275 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1215 | 0.030 |
Why?
|
| Confidentiality | 1 | 2016 | 77 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 148 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 2025 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 687 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 970 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 212 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2018 | 758 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1117 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 240 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 443 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 471 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2014 | 49 | 0.030 |
Why?
|
| Hematoma | 2 | 1985 | 108 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 12 | 0.030 |
Why?
|
| Penetrance | 1 | 2013 | 45 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2309 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2013 | 77 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 159 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 372 | 0.030 |
Why?
|
| Inpatients | 1 | 1996 | 310 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 12 | 0.030 |
Why?
|
| U937 Cells | 1 | 2012 | 32 | 0.030 |
Why?
|
| K562 Cells | 1 | 2012 | 44 | 0.030 |
Why?
|
| Cytosine | 1 | 2013 | 129 | 0.030 |
Why?
|
| Publishing | 1 | 2014 | 90 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 9295 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 198 | 0.030 |
Why?
|
| Haploinsufficiency | 1 | 2012 | 65 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2012 | 261 | 0.030 |
Why?
|
| Adult | 4 | 2019 | 26742 | 0.020 |
Why?
|
| Risk Factors | 1 | 2022 | 5522 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 2 | 1985 | 341 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 266 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 376 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 512 | 0.020 |
Why?
|
| Silencer Elements, Transcriptional | 1 | 2011 | 5 | 0.020 |
Why?
|
| Insulator Elements | 1 | 2011 | 7 | 0.020 |
Why?
|
| Histone Code | 1 | 2011 | 19 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 482 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 795 | 0.020 |
Why?
|
| RNA, Small Untranslated | 1 | 2010 | 15 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 290 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 842 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 887 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 70 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2010 | 55 | 0.020 |
Why?
|
| Genes, Insect | 1 | 2010 | 183 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2886 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2003 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 6360 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2579 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 516 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2019 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6847 | 0.020 |
Why?
|
| Spinal Cord Diseases | 1 | 1986 | 29 | 0.020 |
Why?
|
| Birth Injuries | 1 | 1985 | 4 | 0.020 |
Why?
|
| Orbital Fractures | 1 | 1985 | 14 | 0.020 |
Why?
|
| Skull Fractures | 1 | 1985 | 25 | 0.020 |
Why?
|
| Mastoid | 1 | 1985 | 17 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2411 | 0.020 |
Why?
|
| Brain Edema | 1 | 1985 | 58 | 0.020 |
Why?
|
| Brain Concussion | 1 | 1985 | 65 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1985 | 140 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1985 | 315 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 26129 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 11814 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1985 | 2665 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1998 | 177 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1998 | 265 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1998 | 225 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1996 | 83 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 1977 | 191 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1996 | 145 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1996 | 187 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1977 | 229 | 0.010 |
Why?
|
| Cognition | 1 | 1998 | 579 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1977 | 589 | 0.010 |
Why?
|
| Contrast Media | 1 | 1998 | 1092 | 0.010 |
Why?
|
| Biomarkers | 1 | 1998 | 1771 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1996 | 785 | 0.010 |
Why?
|
| Haplorhini | 1 | 1977 | 81 | 0.000 |
Why?
|
| Hypotension | 1 | 1977 | 71 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1977 | 365 | 0.000 |
Why?
|
| Hypertension | 1 | 1977 | 747 | 0.000 |
Why?
|